Bausch Health Shares Tumble Following Unsuccessful Hepatic Encephalopathy Trials
Bausch Health's stock experienced an 8% decline after the pharmaceutical firm disclosed that its Phase 3 trials investigating amorphous-rifaximin SSD for preventing initial hepatic encephalopathy episodes in adults with liver cirrhosis did not achieve the primary efficacy goals. Despite the trials demonstrating the drug's safety and tolerability, t…